TCR2 Therapeutics (TCRR) PT Raised to $32 at Wedbush

Go back to TCR2 Therapeutics (TCRR) PT Raised to $32 at Wedbush

TCR2 Therapeutics (TCRR) Prices 8M Share Common Offering at $15.50/Sh

July 29, 2020 5:47 AM EDT

TCR2 Therapeutics Inc. (NASDAQ: TCRR) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $15.50 per share. TCR2 also granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be $124.0 million, excluding any exercise of the underwriters option to... More

TCR2 Therapeutics (TCRR) PT Raised to $45 at BMO Capital

July 27, 2020 7:57 AM EDT

BMO Capital analyst Do Kim raised the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $45.00 (from $35.00) while maintaining a Outperform rating.

The analyst commented, "We raise our estimates and target price to $45 from $35, following 2 PRs (40% ORR) in the first dose level of Phase 1.... More